ALLMedicine™ Ulcerative Colitis Center
Research & Reviews 20,173 results
https://doi.org/10.5009/gnl15011
Gut and Liver; Moon JR, Lee CK et. al.
Jan 14th, 2021 - Corrigendum: Unmet Psychosocial Needs of Patients Newly Diagnosed with Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea.|2021|Moon JR,Lee CK,Hong SN,Im JP,Ye BD,|
https://doi.org/10.1007/s11605-020-04884-0 10.1097/SLA.0b013e318187ed64. 10.1097/SLA.0b013e31827d99a2 10.1097/mib.0000000000001061 10.1159/000085356 10.1111/j.1572-0241.2004.40604.x 10.1002/ibd.20661. 10.1016/S0140-6736(15)00465-1 10.3748/wjg.v23.i27.4958 10.1136/gut.2005.082909. 10.1007/BF02253493 10.1136/gutjnl-2011-300777 10.1002/ibd.21911 10.1097/MIB.0b013e3182802b3e 10.1111/apt.12176 10.4065/81.11.1462 10.15585/mmwr.mm6845a2 10.1007/DCR.0b013e3181a4f9fa 10.1086/339432 10.1038/35079107 10.1007/s100380200067 10.1016/j.crohns.2013.10.014 10.1186/1471-2180-12-94 10.1097/MIB.0000000000000444 10.1128/CVI.00034-06 10.1097/MIB.0b013e318280b19e
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract; O'Brien SJ, Hallion J et. al.
Jan 14th, 2021 - Ileal pouch-anal anastomosis (IPAA) is a common surgical treatment for ulcerative colitis. Afferent limb stenosis is an infrequent complication following IPAA, suggesting underlying Crohn's disease (CD). We hypothesized that CD-related single nucl...
https://doi.org/10.1093/ecco-jcc/jjab012
Journal of Crohn's & Colitis; Sandborn WJ, Feagan BG et. al.
Jan 13th, 2021 - This analysis examined long-term safety and efficacy of ozanimod in patients with moderate-to-severe UC with ≥4 years of follow-up in the phase 2 TOUCHSTONE open-label extension (OLE). Patients receiving placebo or ozanimod HCl 0.5 mg or 1 mg duri...
https://doi.org/10.1080/08923973.2021.1872617
Immunopharmacology and Immunotoxicology; Ingawale DK, Mandlik SK et. al.
Jan 13th, 2021 - Ulcerative colitis is common types of severe, progressive, idiopathic inflammatory bowel disease that involves the mucosal lining of the large intestine. The purpose of the study is to explore the effects of hecogenin in TNBS (2, 4, 6- trinitroben...
https://doi.org/10.1186/s40168-020-00967-x 10.1146/annurev-biochem-062917-012848 10.1111/1574-6976.12050 10.1038/s41467-018-07228-4 10.1074/jbc.M808686200 10.1021/acssynbio.9b00358 10.1016/j.devcel.2015.08.009 10.1126/science.1061315 10.1016/S0022-2836(03)00922-7 10.1038/s41564-018-0306-4 10.1038/s41586-019-1237-9 10.1038/nmicrobiol.2017.4 10.1038/s41564-017-0089-z 10.1186/s40168-019-0618-5 10.1021/ac303053e 10.1186/s40168-019-0631-8 10.1186/s40168-017-0290-6 10.1186/s40168-016-0176-z 10.1038/s41467-018-05357-4 10.1021/pr300955f 10.1038/s41467-019-10513-5 10.1038/nbt.3418 10.1038/nbt.2942 10.1038/nature17645 10.1038/s41587-018-0008-8 10.1093/bioinformatics/btq461 10.1074/mcp.M111.010587 10.1038/nbt.1511 10.1038/nbt.4236 10.1021/pr101065j 10.1021/ac9016693 10.1021/pr300576s 10.1021/acs.jproteome.8b00716 10.1016/S0006-291X(67)80055-X 10.1101/gr.849004 10.1093/nar/gky310 10.1093/nar/gkx295 10.1371/journal.pone.0027173 10.1186/s12864-016-2855-3 10.1016/j.cels.2018.08.009 10.1074/mcp.M115.055103 10.1038/nature15377 10.1002/jcp.1041500323 10.1002/pmic.201400560 10.1128/AEM.66.12.5128-5133.2000 10.1128/AEM.68.6.2809-2813.2002 10.1128/JB.06737-11 10.1016/j.crohns.2008.06.001 10.1016/S0140-6736(16)32126-2 10.1136/gutjnl-2015-309147 10.1136/gutjnl-2011-300775 10.1371/journal.pone.0066074 10.1186/s40168-018-0604-3 10.1136/gutjnl-2018-317571 10.1126/scitranslmed.aaf9655
Microbiome Yan Z, He F et. al.
Jan 13th, 2021 - Proteolysis regulation allows gut microbes to respond rapidly to dynamic intestinal environments by fast degradation of misfolded proteins and activation of regulatory proteins. However, alterations of gut microbial proteolytic signatures under co...
Guidelines 87 results
https://doi.org/10.1016/j.gastrohep.2020.05.009
Annals of the New York Academy of Sciences References; Muñoz F, Ripollés T et. al.
Sep 26th, 2020 - Ultrasound has an excellent diagnostic performance when Crohn's disease is suspected, when performing an activity assessment, or determining the extension and location of Crohn's disease, very similar to other examinations such as MRI or CT. It ha...
https://doi.org/10.1053/j.gastro.2020.03.011
Gastroenterology
Mar 28th, 2020 - Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcerative Colitis: Clinical Decision Support Tool.|2020| ,|
https://doi.org/10.1053/j.gastro.2020.03.012
Gastroenterology Feuerstein JD, Isaacs KL et. al.
Mar 14th, 2020 - Spotlight: Management of Moderate-to-Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175923
Gastroenterology Feuerstein JD, Isaacs KL et. al.
Jan 16th, 2020 - AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|therapeutic use,standards,diagnosis,immunology,therapy,diagnostic imaging,immunology,p...
https://doi.org/10.1136/bmj.l5897
BMJ (Clinical Research Ed.); Abdulrazeg O, Li B et. al.
Oct 29th, 2019 - Management of ulcerative colitis: summary of updated NICE guidance.|2019|Abdulrazeg O,Li B,Epstein J, ,|drug therapy,methods,therapeutic use,drug therapy,drug therapy,
Drugs 283 results see all →
Clinicaltrials.gov 21,231 results
https://doi.org/10.5009/gnl15011
Gut and Liver; Moon JR, Lee CK et. al.
Jan 14th, 2021 - Corrigendum: Unmet Psychosocial Needs of Patients Newly Diagnosed with Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea.|2021|Moon JR,Lee CK,Hong SN,Im JP,Ye BD,|
https://doi.org/10.1007/s11605-020-04884-0 10.1097/SLA.0b013e318187ed64. 10.1097/SLA.0b013e31827d99a2 10.1097/mib.0000000000001061 10.1159/000085356 10.1111/j.1572-0241.2004.40604.x 10.1002/ibd.20661. 10.1016/S0140-6736(15)00465-1 10.3748/wjg.v23.i27.4958 10.1136/gut.2005.082909. 10.1007/BF02253493 10.1136/gutjnl-2011-300777 10.1002/ibd.21911 10.1097/MIB.0b013e3182802b3e 10.1111/apt.12176 10.4065/81.11.1462 10.15585/mmwr.mm6845a2 10.1007/DCR.0b013e3181a4f9fa 10.1086/339432 10.1038/35079107 10.1007/s100380200067 10.1016/j.crohns.2013.10.014 10.1186/1471-2180-12-94 10.1097/MIB.0000000000000444 10.1128/CVI.00034-06 10.1097/MIB.0b013e318280b19e
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract; O'Brien SJ, Hallion J et. al.
Jan 14th, 2021 - Ileal pouch-anal anastomosis (IPAA) is a common surgical treatment for ulcerative colitis. Afferent limb stenosis is an infrequent complication following IPAA, suggesting underlying Crohn's disease (CD). We hypothesized that CD-related single nucl...
https://doi.org/10.1093/ecco-jcc/jjab012
Journal of Crohn's & Colitis; Sandborn WJ, Feagan BG et. al.
Jan 13th, 2021 - This analysis examined long-term safety and efficacy of ozanimod in patients with moderate-to-severe UC with ≥4 years of follow-up in the phase 2 TOUCHSTONE open-label extension (OLE). Patients receiving placebo or ozanimod HCl 0.5 mg or 1 mg duri...
https://doi.org/10.1080/08923973.2021.1872617
Immunopharmacology and Immunotoxicology; Ingawale DK, Mandlik SK et. al.
Jan 13th, 2021 - Ulcerative colitis is common types of severe, progressive, idiopathic inflammatory bowel disease that involves the mucosal lining of the large intestine. The purpose of the study is to explore the effects of hecogenin in TNBS (2, 4, 6- trinitroben...
https://doi.org/10.1186/s40168-020-00967-x 10.1146/annurev-biochem-062917-012848 10.1111/1574-6976.12050 10.1038/s41467-018-07228-4 10.1074/jbc.M808686200 10.1021/acssynbio.9b00358 10.1016/j.devcel.2015.08.009 10.1126/science.1061315 10.1016/S0022-2836(03)00922-7 10.1038/s41564-018-0306-4 10.1038/s41586-019-1237-9 10.1038/nmicrobiol.2017.4 10.1038/s41564-017-0089-z 10.1186/s40168-019-0618-5 10.1021/ac303053e 10.1186/s40168-019-0631-8 10.1186/s40168-017-0290-6 10.1186/s40168-016-0176-z 10.1038/s41467-018-05357-4 10.1021/pr300955f 10.1038/s41467-019-10513-5 10.1038/nbt.3418 10.1038/nbt.2942 10.1038/nature17645 10.1038/s41587-018-0008-8 10.1093/bioinformatics/btq461 10.1074/mcp.M111.010587 10.1038/nbt.1511 10.1038/nbt.4236 10.1021/pr101065j 10.1021/ac9016693 10.1021/pr300576s 10.1021/acs.jproteome.8b00716 10.1016/S0006-291X(67)80055-X 10.1101/gr.849004 10.1093/nar/gky310 10.1093/nar/gkx295 10.1371/journal.pone.0027173 10.1186/s12864-016-2855-3 10.1016/j.cels.2018.08.009 10.1074/mcp.M115.055103 10.1038/nature15377 10.1002/jcp.1041500323 10.1002/pmic.201400560 10.1128/AEM.66.12.5128-5133.2000 10.1128/AEM.68.6.2809-2813.2002 10.1128/JB.06737-11 10.1016/j.crohns.2008.06.001 10.1016/S0140-6736(16)32126-2 10.1136/gutjnl-2015-309147 10.1136/gutjnl-2011-300775 10.1371/journal.pone.0066074 10.1186/s40168-018-0604-3 10.1136/gutjnl-2018-317571 10.1126/scitranslmed.aaf9655
Microbiome Yan Z, He F et. al.
Jan 13th, 2021 - Proteolysis regulation allows gut microbes to respond rapidly to dynamic intestinal environments by fast degradation of misfolded proteins and activation of regulatory proteins. However, alterations of gut microbial proteolytic signatures under co...
News 1,143 results
https://www.medscape.com/viewarticle/941486
Nov 23rd, 2020 - Takeaway The persistence rates of antitumour necrosis factor agents golimumab and adalimumab as first-line or second-line biologic therapy for ulcerative colitis (UC) were above 64.0% at 12 months following treatment initiation. In addition, the 1...
https://www.staging.medscape.com/viewarticle/940931
Nov 12th, 2020 - Among patients with ulcerative colitis who were treated in routine practice, a point-based clinical scoring tool predicted nonresponse to vedolizumab therapy, according to study findings published online in Clinical Gastroenterology and Hepatology...
https://www.medscape.com/viewarticle/940931
Nov 12th, 2020 - Among patients with ulcerative colitis who were treated in routine practice, a point-based clinical scoring tool predicted nonresponse to vedolizumab therapy, according to study findings published online in Clinical Gastroenterology and Hepatology...
https://www.staging.medscape.com/viewarticle/940615
Nov 9th, 2020 - (Reuters) - People with inflammatory bowel disease (IBD) do not increase their risk for COVID-19 by taking immunosuppressive drugs to control their symptoms, according to a study of more than 5,300 patients with Crohn's disease or ulcerative colit...
https://www.medscape.com/viewarticle/940615
Nov 9th, 2020 - (Reuters) - People with inflammatory bowel disease (IBD) do not increase their risk for COVID-19 by taking immunosuppressive drugs to control their symptoms, according to a study of more than 5,300 patients with Crohn's disease or ulcerative colit...
